Maintenance of Changes in Weight. The initial mean weight
reduction from baseline at 52 weeks with dapagliflozin
(−3.4 kg) and weight gain with glipizide (1.6 kg) remained
relatively stable at 104 weeks with dapagliflozin (−3.7 kg; 95%
CI −4.2, −3.2) and glipizide (1.4 kg; 95% CI 0.9, 1.8; Figure 1E),
resulting in a dapagliflozin versus glipizide difference at
104 weeks of −5.1 kg (95% CI −5.7, −4.4).